{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T10:48:01Z","timestamp":1784630881087,"version":"3.55.0"},"reference-count":49,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2015,1,1]],"date-time":"2015-01-01T00:00:00Z","timestamp":1420070400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,1,1]],"date-time":"2015-01-01T00:00:00Z","timestamp":1420070400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["molpharm.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Pharmacology"],"published-print":{"date-parts":[[2015,1]]},"DOI":"10.1124\/mol.114.095190","type":"journal-article","created":{"date-parts":[[2014,10,16]],"date-time":"2014-10-16T02:49:44Z","timestamp":1413427784000},"page":"31-38","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["P-Retigabine: An N-Propargyled Retigabine with Improved Brain Distribution and Enhanced Antiepileptic Activity"],"prefix":"10.1016","volume":"87","author":[{"given":"Pingzheng","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yangming","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiyan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueqin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoying","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoping","family":"Pi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lipeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Zhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fajun","family":"Nan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaobing","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/mol.114.095190_bib1","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/384078a0","article-title":"K(V)LQT1 and lsK (minK) proteins associate to form the I(Ks) cardiac potassium current","volume":"384","author":"Barhanin","year":"1996","journal-title":"Nature"},{"key":"10.1124\/mol.114.095190_bib2","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.eplepsyres.2010.09.001","article-title":"Progress report on new antiepileptic drugs: a summary of the Tenth Eilat Conference (EILAT X)","volume":"92","author":"Bialer","year":"2010","journal-title":"Epilepsy Res"},{"key":"10.1124\/mol.114.095190_bib3","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/nrd2997","article-title":"Key factors in the discovery and development of new antiepileptic drugs","volume":"9","author":"Bialer","year":"2010","journal-title":"Nat Rev Drug Discov"},{"key":"10.1124\/mol.114.095190_bib4","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1111\/j.1528-1167.2012.03441.x","article-title":"The urinary safety profile and secondary renal effects of retigabine (ezogabine): a first-in-class antiepileptic drug that targets KCNQ (K(v)7) potassium channels","volume":"53","author":"Brickel","year":"2012","journal-title":"Epilepsia"},{"key":"10.1124\/mol.114.095190_bib5","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/j.seizure.2010.10.027","article-title":"Antiepileptic drug therapy the story so far","volume":"19","author":"Brodie","year":"2010","journal-title":"Seizure"},{"key":"10.1124\/mol.114.095190_bib6","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1111\/j.1476-5381.2009.00111.x","article-title":"Neural KCNQ (Kv7) channels","volume":"156","author":"Brown","year":"2009","journal-title":"Br J Pharmacol"},{"key":"10.1124\/mol.114.095190_bib7","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/S0006-8993(98)01258-X","article-title":"Behavioral phenotyping of transgenic and knockout mice: experimental design and evaluation of general health, sensory functions, motor abilities, and specific behavioral tests","volume":"835","author":"Crawley","year":"1999","journal-title":"Brain Res"},{"key":"10.1124\/mol.114.095190_bib8","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1002\/jps.3030460322","article-title":"A note on a simple apparatus for detecting neurological deficit in rats and mice","volume":"46","author":"Dunham","year":"1957","journal-title":"J Am Pharm Assoc Am Pharm Assoc (Baltim)"},{"key":"10.1124\/mol.114.095190_bib9","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1517\/14740338.2013.823399","article-title":"Safety profile of two novel antiepileptic agents approved for the treatment of refractory partial seizures: ezogabine (retigabine) and perampanel","volume":"12","author":"Faulkner","year":"2013","journal-title":"Expert Opin Drug Saf"},{"key":"10.1124\/mol.114.095190_bib10","doi-asserted-by":"crossref","first-page":"28322","DOI":"10.1074\/jbc.M110.116392","article-title":"Isoform-specific prolongation of Kv7 (KCNQ) potassium channel opening mediated by new molecular determinants for drug-channel interactions","volume":"285","author":"Gao","year":"2010","journal-title":"J Biol Chem"},{"key":"10.1124\/mol.114.095190_bib11","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1111\/j.1528-1167.2011.03365.x","article-title":"The mechanism of action of retigabine (ezogabine), a first-in-class K+ channel opener for the treatment of epilepsy","volume":"53","author":"Gunthorpe","year":"2012","journal-title":"Epilepsia"},{"key":"10.1124\/mol.114.095190_bib12","doi-asserted-by":"crossref","first-page":"10253","DOI":"10.1523\/JNEUROSCI.2596-06.2006","article-title":"M-like K+ currents in type I hair cells and calyx afferent endings of the developing rat utricle","volume":"26","author":"Hurley","year":"2006","journal-title":"J Neurosci"},{"key":"10.1124\/mol.114.095190_bib13","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/35036198","article-title":"Neuronal KCNQ potassium channels: physiology and role in disease","volume":"1","author":"Jentsch","year":"2000","journal-title":"Nat Rev Neurosci"},{"key":"10.1124\/mol.114.095190_bib14","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1159\/000158538","article-title":"Expression and localization of K channels KCNQ2 and KCNQ3 in the mammalian cochlea","volume":"14","author":"Jin","year":"2009","journal-title":"Audiol Neurootol"},{"key":"10.1124\/mol.114.095190_bib15","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/0920-1211(95)00050-X","article-title":"The effects of D-23129, a new experimental anticonvulsant drug, on neurotransmitter amino acids in the rat hippocampus in vitro","volume":"22","author":"Kapetanovic","year":"1995","journal-title":"Epilepsy Res"},{"key":"10.1124\/mol.114.095190_bib16","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1124\/mol.108.052282","article-title":"Refinement of the binding site and mode of action of the anticonvulsant Retigabine on KCNQ K+ channels","volume":"75","author":"Lange","year":"2009","journal-title":"Mol Pharmacol"},{"key":"10.1124\/mol.114.095190_bib17","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1111\/j.1528-1167.2011.03364.x","article-title":"The spectrum of anticonvulsant efficacy of retigabine (ezogabine) in animal models: implications for clinical use","volume":"53","author":"Large","year":"2012","journal-title":"Epilepsia"},{"key":"10.1124\/mol.114.095190_bib18","doi-asserted-by":"crossref","first-page":"459","DOI":"10.2174\/138161206775474477","article-title":"Modulation of potassium channels as a therapeutic approach","volume":"12","author":"Lawson","year":"2006","journal-title":"Curr Pharm Des"},{"key":"10.1124\/mol.114.095190_bib19","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1038\/nn.2351","article-title":"Regulation of AMPA receptor extrasynaptic insertion by 4.1N, phosphorylation and palmitoylation","volume":"12","author":"Lin","year":"2009","journal-title":"Nat Neurosci"},{"key":"10.1124\/mol.114.095190_bib20","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1124\/mol.108.049825","article-title":"Cardiovascular KCNQ (Kv7) potassium channels: physiological regulators and new targets for therapeutic intervention","volume":"74","author":"Mackie","year":"2008","journal-title":"Mol Pharmacol"},{"key":"10.1124\/mol.114.095190_bib21","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S0026-895X(24)12060-3","article-title":"Modulation of KCNQ2\/3 potassium channels by the novel anticonvulsant retigabine","volume":"58","author":"Main","year":"2000","journal-title":"Mol Pharmacol"},{"key":"10.1124\/mol.114.095190_bib22","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1007\/s00424-008-0567-5","article-title":"Expression and function of K(v)7 channels in murine myometrium throughout oestrous cycle","volume":"457","author":"McCallum","year":"2009","journal-title":"Pflugers Arch"},{"key":"10.1124\/mol.114.095190_bib23","doi-asserted-by":"crossref","first-page":"e4236","DOI":"10.1371\/journal.pone.0004236","article-title":"Discovery of a novel activator of KCNQ1-KCNE1 K channel complexes","volume":"4","author":"Mruk","year":"2009","journal-title":"PLoS ONE"},{"key":"10.1124\/mol.114.095190_bib24","unstructured":"Nan F, Li M, Gao Z, Chen F, Zhang Y, Zhou P, Hu H, Xu H, Liu S (2012) inventors, Shanghai Institute Materia Medica, Chinese Academy of Sciences, assignee. Novel compound as KCNQ potassium channel agonist, preparation method therefor and use thereof. People\u2019s Republic of China patent WO2013\/060097. 23 Oct 2012."},{"key":"10.1124\/mol.114.095190_bib25","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.neulet.2009.08.071","article-title":"The KCNQ2\/3 selective channel opener ICA-27243 binds to a novel voltage-sensor domain site","volume":"465","author":"Padilla","year":"2009","journal-title":"Neurosci Lett"},{"key":"10.1124\/mol.114.095190_bib26","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1046\/j.1471-4159.1998.70051781.x","article-title":"CNS drug design based on principles of blood-brain barrier transport","volume":"70","author":"Pardridge","year":"1998","journal-title":"J Neurochem"},{"key":"10.1124\/mol.114.095190_bib27","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1124\/mol.104.007112","article-title":"Meclofenamic acid and diclofenac, novel templates of KCNQ2\/Q3 potassium channel openers, depress cortical neuron activity and exhibit anticonvulsant properties","volume":"67","author":"Peretz","year":"2005","journal-title":"Mol Pharmacol"},{"key":"10.1124\/mol.114.095190_bib28","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1021\/jm8008597","article-title":"Covalent modifiers: an orthogonal approach to drug design","volume":"52","author":"Potashman","year":"2009","journal-title":"J Med Chem"},{"key":"10.1124\/mol.114.095190_bib29","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.ejphar.2010.03.050","article-title":"Functional effects of the KCNQ modulators retigabine and XE991 in the rat urinary bladder","volume":"638","author":"Rode","year":"2010","journal-title":"Eur J Pharmacol"},{"key":"10.1124\/mol.114.095190_bib30","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/0920-1211(95)00101-8","article-title":"D-23129: a new anticonvulsant with a broad spectrum activity in animal models of epileptic seizures","volume":"23","author":"Rostock","year":"1996","journal-title":"Epilepsy Res"},{"key":"10.1124\/mol.114.095190_bib31","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/S0014-2999(97)01249-1","article-title":"The new anticonvulsant retigabine (D-23129) acts as an opener of K+ channels in neuronal cells","volume":"336","author":"Rundfeldt","year":"1997","journal-title":"Eur J Pharmacol"},{"key":"10.1124\/mol.114.095190_bib32","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1124\/mol.54.1.220","article-title":"A novel benzodiazepine that activates cardiac slow delayed rectifier K+ currents","volume":"54","author":"Salata","year":"1998","journal-title":"Mol Pharmacol"},{"key":"10.1124\/mol.114.095190_bib33","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1038\/384080a0","article-title":"Coassembly of K(V)LQT1 and minK (IsK) proteins to form cardiac I(Ks) potassium channel","volume":"384","author":"Sanguinetti","year":"1996","journal-title":"Nature"},{"key":"10.1124\/mol.114.095190_bib34","doi-asserted-by":"crossref","first-page":"5051","DOI":"10.1523\/JNEUROSCI.0128-05.2005","article-title":"Molecular determinants of KCNQ (Kv7) K+ channel sensitivity to the anticonvulsant retigabine","volume":"25","author":"Schenzer","year":"2005","journal-title":"J Neurosci"},{"key":"10.1124\/mol.114.095190_bib35","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/S0028-3908(01)00029-6","article-title":"KCNQ4 channel activation by BMS-204352 and retigabine","volume":"40","author":"Schr\u00f8der","year":"2001","journal-title":"Neuropharmacology"},{"key":"10.1124\/mol.114.095190_bib36","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1161\/01.RES.0000102866.67863.2B","article-title":"Pharmacological activation of normal and arrhythmia-associated mutant KCNQ1 potassium channels","volume":"93","author":"Seebohm","year":"2003","journal-title":"Circ Res"},{"key":"10.1124\/mol.114.095190_bib37","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.pnpbp.2013.02.001","article-title":"An update on amine oxidase inhibitors: multifaceted drugs","volume":"44","author":"Song","year":"2013","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1124\/mol.114.095190_bib38","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1097\/01.ju.0000138155.33749.f4","article-title":"Urodynamic effects of the K+ channel (KCNQ) opener retigabine in freely moving, conscious rats","volume":"172","author":"Streng","year":"2004","journal-title":"J Urol"},{"key":"10.1124\/mol.114.095190_bib39","first-page":"704","article-title":"A potassium channel, the M-channel, as a therapeutic target","volume":"6","author":"Surti","year":"2005","journal-title":"Curr Opin Investig Drugs"},{"key":"10.1124\/mol.114.095190_bib40","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1113\/jphysiol.2003.039842","article-title":"Effect of the KCNQ potassium channel opener retigabine on single KCNQ2\/3 channels expressed in CHO cells","volume":"549","author":"Tatulian","year":"2003","journal-title":"J Physiol"},{"key":"10.1124\/mol.114.095190_bib41","doi-asserted-by":"crossref","first-page":"5535","DOI":"10.1523\/JNEUROSCI.21-15-05535.2001","article-title":"Activation of expressed KCNQ potassium currents and native neuronal M-type potassium currents by the anti-convulsant drug retigabine","volume":"21","author":"Tatulian","year":"2001","journal-title":"J Neurosci"},{"key":"10.1124\/mol.114.095190_bib42","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1126\/science.282.5395.1890","article-title":"KCNQ2 and KCNQ3 potassium channel subunits: molecular correlates of the M-channel","volume":"282","author":"Wang","year":"1998","journal-title":"Science"},{"key":"10.1124\/mol.114.095190_bib43","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1124\/mol.107.043216","article-title":"N-(6-chloro-pyridin-3-yl)-3,4-difluoro-benzamide (ICA-27243): a novel, selective KCNQ2\/Q3 potassium channel activator","volume":"73","author":"Wickenden","year":"2008","journal-title":"Mol Pharmacol"},{"key":"10.1124\/mol.114.095190_bib44","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1016\/j.bmcl.2004.01.069","article-title":"(S)-N-[1-(4-cyclopropylmethyl-3,4-dihydro-2H-benzo[1,4]oxazin-6-yl)-ethyl]-3-(2-fluoro-phenyl)-acrylamide is a potent and efficacious KCNQ2 opener which inhibits induced hyperexcitability of rat hippocampal neurons","volume":"14","author":"Wu","year":"2004","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1124\/mol.114.095190_bib45","doi-asserted-by":"crossref","first-page":"3197","DOI":"10.1021\/jm034073f","article-title":"(S)-N-[1-(3-morpholin-4-ylphenyl)ethyl]-3-phenylacrylamide: an orally bioavailable KCNQ2 opener with significant activity in a cortical spreading depression model of migraine","volume":"46","author":"Wu","year":"2003","journal-title":"J Med Chem"},{"key":"10.1124\/mol.114.095190_bib46","doi-asserted-by":"crossref","first-page":"2887","DOI":"10.1021\/jm0305826","article-title":"Synthesis and structure-activity relationship of acrylamides as KCNQ2 potassium channel openers","volume":"47","author":"Wu","year":"2004","journal-title":"J Med Chem"},{"key":"10.1124\/mol.114.095190_bib47","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1038\/nrd2983","article-title":"Voltage-gated potassium channels as therapeutic targets","volume":"8","author":"Wulff","year":"2009","journal-title":"Nat Rev Drug Discov"},{"key":"10.1124\/mol.114.095190_bib48","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1124\/mol.104.010793","article-title":"The new anticonvulsant retigabine favors voltage-dependent opening of the Kv7.2 (KCNQ2) channel by binding to its activation gate","volume":"67","author":"Wuttke","year":"2005","journal-title":"Mol Pharmacol"},{"key":"10.1124\/mol.114.095190_bib49","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.tips.2007.11.010","article-title":"Activation of Kv7 (KCNQ) voltage-gated potassium channels by synthetic compounds","volume":"29","author":"Xiong","year":"2008","journal-title":"Trends Pharmacol Sci"}],"container-title":["Molecular Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026895X24029936?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026895X24029936?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/mol.114.095190","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T10:00:18Z","timestamp":1739959218000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0026895X24029936"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,1]]},"references-count":49,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,1]]}},"alternative-id":["S0026895X24029936"],"URL":"https:\/\/doi.org\/10.1124\/mol.114.095190","relation":{},"ISSN":["0026-895X"],"issn-type":[{"value":"0026-895X","type":"print"}],"subject":[],"published":{"date-parts":[[2015,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"P-Retigabine: An N-Propargyled Retigabine with Improved Brain Distribution and Enhanced Antiepileptic Activity","name":"articletitle","label":"Article Title"},{"value":"Molecular Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/mol.114.095190","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2014 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}